Nuvalent Completes Successful Public Offering of Common Stock with Underwriters' Full Exercise Option

Nuvalent Announces Successful Public Offering of Class A Common Stock

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company with a focus on developing targeted therapies for cancer, has recently completed an important financial milestone by closing its underwritten public offering of Class A common stock. On November 20, 2025, Nuvalent announced that it successfully offered 4,950,496 shares at a public price of $101 per share, raising approximately $500 million in gross proceeds before deducting underwriting fees and other costs associated with the offering.

This action signifies a vital step for Nuvalent as it seeks to advance its innovative pipeline aimed at transforming cancer treatment. With its robust research capabilities, Nuvalent specializes in precisely targeted therapies that can address clinically proven kinase targets in various types of cancer. The raised capital will be instrumental in furthering its research and development efforts, particularly for candidates aimed at overcoming resistance to current therapies.

That same day, the underwriters exercised an option to purchase an additional 742,574 shares of Class A common stock from related selling stockholders. This decision illustrates the confidence underwriters have in Nuvalent's future, helping to solidify the total offering as the transaction is expected to propel the company's mission further.

The additional shares were traded at the public offering price, which highlights the strategic partnerships with investment firms such as J.P. Morgan, Jefferies, TD Cowen, and Cantor Fitzgerald, who collectively served as joint book-running managers for the offering. Notably, Nuvalent will not receive any additional proceeds from the additional shares, as the funds will go directly to the selling stockholders, which include Deerfield Healthcare Innovations Fund, L.P., and Deerfield Private Design Fund IV, L.P.

The shares were offered pursuant to an automatically effective registration statement filed with the U.S. Securities and Exchange Commission (SEC) in March 2023. Interested investors can find the final prospectus and related documents on the SEC's official website or through their designated financial institutions.

The Future of Nuvalent

Nuvalent is primarily focused on developing therapies for patients suffering from various forms of lung cancer, particularly targeting ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer. The company employs cutting-edge research methods, including structure-based drug design to create innovative small molecules. Their mission is to address challenges faced by existing treatments, such as drug resistance and side effects.

With significant investment and ongoing research, Nuvalent aims to develop solutions that not only improve the quality of life for cancer patients but also provide longer-lasting responses to treatment. As cancer therapies continue to evolve within the biotech landscape, the success of their recent offering positions them strategically to lead in the development of advanced cancer treatments.

For those interested in learning more about Nuvalent, their ongoing research, and therapeutic advances, further information can be accessed through their website and official communications. This public offering serves as a vital step towards bolstering their mission, enhancing treatment options available to cancer patients, and possibly changing the fate of those battling this formidable disease.

In conclusion, the completion of this public offering marks not just a financial triumph for Nuvalent but also a herald for the future of targeted cancer therapies. With a well-defined strategy and strengthened resources, the company appears poised for success in their endeavors towards innovative cancer solutions.